Mirxes Holding (2629) Stock Overview
A micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
2629 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Mirxes Holding Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$55.40 |
| 52 Week High | HK$49.44 |
| 52 Week Low | HK$27.05 |
| Beta | 0 |
| 1 Month Change | 25.28% |
| 3 Month Change | 83.14% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 84.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2629 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 33.9% | 2.3% | 2.6% |
| 1Y | n/a | 165.9% | 52.8% |
Return vs Industry: Insufficient data to determine how 2629 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2629 performed against the Hong Kong Market.
Price Volatility
| 2629 volatility | |
|---|---|
| 2629 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.7% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2629's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 2629's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 347 | Lihan Zhou | mirxes.com |
Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related products.
Mirxes Holding Company Limited Fundamentals Summary
| 2629 fundamental statistics | |
|---|---|
| Market cap | HK$11.58b |
| Earnings (TTM) | -HK$592.68m |
| Revenue (TTM) | HK$164.74m |
Is 2629 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2629 income statement (TTM) | |
|---|---|
| Revenue | US$21.19m |
| Cost of Revenue | US$9.86m |
| Gross Profit | US$11.32m |
| Other Expenses | US$87.55m |
| Earnings | -US$76.23m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 53.45% |
| Net Profit Margin | -359.78% |
| Debt/Equity Ratio | 15.8% |
How did 2629 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/15 16:12 |
| End of Day Share Price | 2025/09/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mirxes Holding Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.